WO1996005836A3 - Methods of treating cold symptoms using pentoxifylline - Google Patents
Methods of treating cold symptoms using pentoxifylline Download PDFInfo
- Publication number
- WO1996005836A3 WO1996005836A3 PCT/US1995/010840 US9510840W WO9605836A3 WO 1996005836 A3 WO1996005836 A3 WO 1996005836A3 US 9510840 W US9510840 W US 9510840W WO 9605836 A3 WO9605836 A3 WO 9605836A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pentoxifylline
- subject
- methods
- analog
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a method of alleviating a symptom of an upper respiratory viral infection in a subject, comprising administering to the subject an effective amount of pentoxifylline or an analog thereof. The invention also provides a method of inhibiting interleukin-8 elaboration in a subject comprising administering to the subject an effective amount of pentoxifylline or an analog thereof. A pharmaceutical composition for alleviating a symptom of an upper respiratory viral infection is also provided, comprising an effective amount of pentoxifylline or an analog thereof in a pharmaceutically acceptable nasal spray carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU35397/95A AU3539795A (en) | 1994-08-25 | 1995-08-25 | Methods of treating cold symptoms using pentoxifylline |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29648794A | 1994-08-25 | 1994-08-25 | |
US08/296,487 | 1994-08-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996005836A2 WO1996005836A2 (en) | 1996-02-29 |
WO1996005836A3 true WO1996005836A3 (en) | 1996-04-18 |
Family
ID=23142202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/010840 WO1996005836A2 (en) | 1994-08-25 | 1995-08-25 | Methods of treating cold symptoms using pentoxifylline |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3539795A (en) |
WO (1) | WO1996005836A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856330A (en) * | 1996-07-31 | 1999-01-05 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin |
BR0112603A (en) * | 2000-07-18 | 2004-08-24 | Smithkline Beecham Corp | Use of il-8 receptor antagonists in the treatment of virus infections. |
BRPI0908107A2 (en) | 2008-02-29 | 2019-09-24 | Concert Pharmaceuticals Inc | substituted xanthine derivative, pharmaceutical composition comprising such a compound, methods of treating a disease or condition in a patient in need thereof, method of treating chronic kidney disease, liver disease, diabetes-related and intermittent claudication |
US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
EP2473052A4 (en) | 2009-09-02 | 2013-03-20 | Concert Pharmaceuticals Inc | Substituted xanthine derivatives |
GB2475359A (en) * | 2009-11-11 | 2011-05-18 | Biocopea Ltd | A compound for use in treating a fulminant respiratory disorder |
EP2611807A2 (en) | 2010-09-01 | 2013-07-10 | Concert Pharmaceuticals Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione |
WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
US9328113B2 (en) | 2012-04-13 | 2016-05-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2013159006A1 (en) | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279079A2 (en) * | 1986-12-31 | 1988-08-24 | Hoechst-Roussel Pharmaceuticals Incorporated | Purine derivatives as interleukin-1 inhibitors |
US5096906A (en) * | 1986-12-31 | 1992-03-17 | University Of Virginia Alumni Patents Foundation | Method of inhibiting the activity of leukocyte derived cytokines |
US5196429A (en) * | 1986-12-31 | 1993-03-23 | Hoechst-Roussel Pharmaceuticals Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5196430A (en) * | 1986-12-31 | 1993-03-23 | Hoechst-Roussel Pharmaceuticals Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5272153A (en) * | 1986-12-31 | 1993-12-21 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
EP0609606A1 (en) * | 1992-10-01 | 1994-08-10 | The Wellcome Foundation Limited | Tucaresol as an immunopotentiatory agent |
-
1995
- 1995-08-25 WO PCT/US1995/010840 patent/WO1996005836A2/en active Application Filing
- 1995-08-25 AU AU35397/95A patent/AU3539795A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279079A2 (en) * | 1986-12-31 | 1988-08-24 | Hoechst-Roussel Pharmaceuticals Incorporated | Purine derivatives as interleukin-1 inhibitors |
US5096906A (en) * | 1986-12-31 | 1992-03-17 | University Of Virginia Alumni Patents Foundation | Method of inhibiting the activity of leukocyte derived cytokines |
US5196429A (en) * | 1986-12-31 | 1993-03-23 | Hoechst-Roussel Pharmaceuticals Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5196430A (en) * | 1986-12-31 | 1993-03-23 | Hoechst-Roussel Pharmaceuticals Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
US5272153A (en) * | 1986-12-31 | 1993-12-21 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
EP0609606A1 (en) * | 1992-10-01 | 1994-08-10 | The Wellcome Foundation Limited | Tucaresol as an immunopotentiatory agent |
EP0678298A2 (en) * | 1992-10-01 | 1995-10-25 | The Wellcome Foundation Limited | Use of 4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid as immopotentiatory agent |
Non-Patent Citations (6)
Title |
---|
A.M.VAN FURTH: "In Vitro Effect of Dexamethasone, Pentoxifylline..", PEDIATRIC RESEARCH, vol. 35, no. 6, pages 725 - 728 * |
G.C.RICE ET AL.: "CT-1501R SELECTIVELY INHIBITS INDUCED INFLAMMATORY MONOKINES IN HUMAN WHOLE BLOOD EX VIVO", SHOCK, vol. 1, no. 4, pages 254 - 266 * |
K.D.YANG ET AL.: "Neuroblastoma Cell-Mediated Leukocyte Chemotaxis: Lineage-Specific Differentiation of Interleukin-8 Expression", EXPERIMENTAL CELL RESEARCH, vol. 211, no. 1, pages 1 - 5 * |
P.NEUNER ET AL.: "Pentoxifylline in vivo down-regulates the release of IL-1beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells", IMMUNOLOGY, vol. 83, no. 2, pages 262 - 267 * |
R.B.TURNER, ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 34, pages 65 * |
S.MIKI ET AL.: "Effects of propentofylline on the production of IFN-.gamma. and IL-8 by peripheral blood mononuclear cells in vitro", DIALOG INFORMATION SERVICES, FILE 399: CA SEARCH, ABSTRACT 118: 32686Z * |
Also Published As
Publication number | Publication date |
---|---|
AU3539795A (en) | 1996-03-14 |
WO1996005836A2 (en) | 1996-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1555025A3 (en) | Use of dehydroepiandrosterone analogs for the treatment of asthma | |
EP0911033A3 (en) | Methods and compositions for the treatment of diseases with interferon while reducing side effects | |
CA2155933A1 (en) | Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins | |
EP1029540A3 (en) | Use of droloxifene for the treatment of cardiovascular diseases | |
UA41906C2 (en) | Method for treating neurological disorders due to trauma | |
CA2146954A1 (en) | Breath activated nicotine inhalers | |
CA2184077A1 (en) | Nasal and ocular administration of ketamine to manage pain and for detoxification | |
CA2155200A1 (en) | Use of topical anesthetics for the treatment of eosinophil-associated diseases | |
CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
SG166294G (en) | Inhalation medicaments for treating respiratory disorders | |
CA2150185A1 (en) | Pharmaceutical composition for the treatment of stoma-peripheral inflammation | |
MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
EP0352025A3 (en) | Use of nalmefene in the treatment of allergic rhinitis | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
WO1996005836A3 (en) | Methods of treating cold symptoms using pentoxifylline | |
CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
CA2139385A1 (en) | Products containing g-csf and tnf binding protein | |
WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
WO2000008007A3 (en) | Cyclopentabenzofuran derivatives and their use | |
CA2150183A1 (en) | Pharmaceutical composition for the treatment of hemorrhoidal diseases | |
WO1999061010A3 (en) | Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound | |
EP0657167A3 (en) | Use of oenotheine B for the manufacture of a medicament for the treatment of disorders related to hyperandrogenism, pharmaceutical compositions containing oenotheine B and a process for its preparation from epilobium parviflorum. | |
ZA925146B (en) | Pharmaceutical agent for treatment of withdrawal symptoms. | |
AU1116895A (en) | Use of theophylline for the manufacture of a medicament for the treatment of asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |